Systematic review: Infliximab therapy in ulcerative colitis.
about
Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisExtracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.Innovative therapeutics for inflammatory bowel diseaseThe impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis.Therapeutic strategies for the management of ulcerative colitis.Therapeutic options in acute severe ulcerative colitis.Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial.Review article: the optimal medical management of acute severe ulcerative colitis.Genetics of ulcerative colitis.Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.Immunosuppressive and biologic therapy for ulcerative colitis.Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis.Management of inflammatory bowel disease in poor responders to infliximab.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Surgical and medical treatment in patients with acute severe ulcerative colitis.The biologics of ulcerative colitis.Infliximab in ulcerative colitis.Navigating the complexity of ulcerative colitis: challenging case example.Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis.Associated comorbidities in psoriasis and inflammatory bowel disease.Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation.A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.Infliximab for the treatment of ulcerative colitis.Evidence-based clinical practice guidelines for inflammatory bowel disease.Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis
P2860
Q28657925-E21EECD3-3AF4-4952-9384-ECA1788BFE1DQ35026302-D0A740C2-3A45-4B93-B983-CB4AF71925B8Q35026410-9AC05C5A-9597-45A5-990B-E358D5868955Q35645531-DDEEB7A6-5BF2-409B-A088-59E5F87870D7Q35752240-3977A6A1-1172-45DD-B874-6A82E87C5C74Q36378458-D09DB418-6F11-47D2-847A-06239799B129Q36802524-52B7D1E9-285C-4869-B330-F95EE4D75024Q37197292-445B0248-96A2-4962-BDF2-721D10F5CFACQ37256032-64D7192E-1EB3-4439-A7EE-7BAAB3CED982Q37318035-7046CD56-7191-468E-ACC3-7EB956F4C37CQ37345935-1639F3B8-F732-4F3B-913C-93F359C775F3Q37681244-5BE6F612-FCDE-408B-9DFA-F3E31C7A511CQ37772188-3410F939-EADF-47A8-A90C-74A9C870D8ADQ37841401-D8FA2EF5-2135-420E-8183-00F24A12CAE1Q37853359-D526529F-BCB5-45C1-A0CB-33F6F2EDB7E4Q37964767-D47AF5A6-8E0D-49A7-BDEE-CC24A5C9AE73Q38060831-CE2BF0AF-41C1-4BCC-8096-78106BF45DBAQ38104612-13F56A03-DC21-4886-96FD-5D88EBCEFC6BQ38113455-217FB546-A4FA-42EA-9B76-E401394B53D4Q38180195-335220DD-ACC3-4C2B-9205-893F6D7554B7Q38191583-2314317E-E3C5-41AD-BF05-B76BE2F93133Q38222449-5344DDBD-554D-4B3F-85DC-9B433BA4F528Q38254573-289D1480-2E5B-4BD1-ADA9-27D1D49E9137Q38302725-4802B4EA-2F84-4AD6-90CD-B8C2D8E0AEABQ38365426-F00184D7-310C-417B-907B-1C5882C6697CQ38575522-B02F1C05-752D-4014-8EEF-1CDAD6D78C22Q39037681-017191B2-91AF-4F1E-9783-1457730F9928Q41860347-23EE1810-95A2-4F06-B663-8169EFF21ABDQ42648170-29679604-6372-48D4-AC94-A4FD5C5C043FQ44979663-3D521AFA-D4F9-492A-A72A-B8678BBCD319Q45907246-3BCB0673-B1AB-46A0-B1C5-90CA01731C87Q46691006-D5D287E5-E131-4842-8E2F-56444A8BB916Q46846798-B348E262-88D2-4D8F-AB25-65E357B49E60Q47682064-953A0C45-36F5-42D6-B4FF-100984266D7EQ50079201-340E8F76-72BC-4EB8-80FC-4D78FD04F618Q50685553-9F402474-4780-498F-AA35-526E7B829562Q58694439-6A593F04-A841-445D-B12A-25A395E94BBC
P2860
Systematic review: Infliximab therapy in ulcerative colitis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systematic review: Infliximab therapy in ulcerative colitis.
@ast
Systematic review: Infliximab therapy in ulcerative colitis.
@en
type
label
Systematic review: Infliximab therapy in ulcerative colitis.
@ast
Systematic review: Infliximab therapy in ulcerative colitis.
@en
prefLabel
Systematic review: Infliximab therapy in ulcerative colitis.
@ast
Systematic review: Infliximab therapy in ulcerative colitis.
@en
P1476
Systematic review: Infliximab therapy in ulcerative colitis
@en
P2093
Y González-Lama
P356
10.1111/J.1365-2036.2006.03131.X
P407
P577
2007-01-01T00:00:00Z